Prolonged clinical benefit from the maintenance hormone therapy inpatients with metastatic breast cancer

Seungtaek Lim, Soohyeon Lee, Jungwoo Han, Byeongwoo Park, Seung Il Kim, Seho Park, Joo Hang Kim, Hye Jin Choi, Joohyuk Sohn

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective: We investigated the efficacy of maintenance hormone therapy (MHT), which was given to hormone positive metastatic breast cancer (MBC) patients in non-progression status to the previous chemotherapy. Methods: This study retrospectively analyzed 76 MBC patients who had been treated with MHT from 2006 to 2010 at a single institute. Results: For the 76 patients reviewed, the median progression free survival (PFS) to MHT was 14.4 months (95% CI,11.6-17.3). Prolonged PFS was associated with less previous palliative chemotherapy, fewer metastatic sites, and the absence of visceral metastasis in univariate analysis. Multivariate analysis showed that only the number of previous palliative chemotherapy (HR 1.73, 95% CI, 1.00-2.98; P=0.04) remained as a significant variable. MHT was generally well tolerated. Conclusions: MHT showed considerable efficacy and tolerability in this study. Further randomized prospective study is warranted.

Original languageEnglish
Pages (from-to)1205-1209
Number of pages5
JournalBreast
Volume22
Issue number6
DOIs
Publication statusPublished - 2013 Dec 1

Fingerprint

Inpatients
Maintenance
Hormones
Breast Neoplasms
Drug Therapy
Disease-Free Survival
Therapeutics
Multivariate Analysis
Prospective Studies
Neoplasm Metastasis

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Lim, Seungtaek ; Lee, Soohyeon ; Han, Jungwoo ; Park, Byeongwoo ; Kim, Seung Il ; Park, Seho ; Kim, Joo Hang ; Choi, Hye Jin ; Sohn, Joohyuk. / Prolonged clinical benefit from the maintenance hormone therapy inpatients with metastatic breast cancer. In: Breast. 2013 ; Vol. 22, No. 6. pp. 1205-1209.
@article{3e227dd19a714451a060a5966bce04c5,
title = "Prolonged clinical benefit from the maintenance hormone therapy inpatients with metastatic breast cancer",
abstract = "Objective: We investigated the efficacy of maintenance hormone therapy (MHT), which was given to hormone positive metastatic breast cancer (MBC) patients in non-progression status to the previous chemotherapy. Methods: This study retrospectively analyzed 76 MBC patients who had been treated with MHT from 2006 to 2010 at a single institute. Results: For the 76 patients reviewed, the median progression free survival (PFS) to MHT was 14.4 months (95{\%} CI,11.6-17.3). Prolonged PFS was associated with less previous palliative chemotherapy, fewer metastatic sites, and the absence of visceral metastasis in univariate analysis. Multivariate analysis showed that only the number of previous palliative chemotherapy (HR 1.73, 95{\%} CI, 1.00-2.98; P=0.04) remained as a significant variable. MHT was generally well tolerated. Conclusions: MHT showed considerable efficacy and tolerability in this study. Further randomized prospective study is warranted.",
author = "Seungtaek Lim and Soohyeon Lee and Jungwoo Han and Byeongwoo Park and Kim, {Seung Il} and Seho Park and Kim, {Joo Hang} and Choi, {Hye Jin} and Joohyuk Sohn",
year = "2013",
month = "12",
day = "1",
doi = "10.1016/j.breast.2013.08.013",
language = "English",
volume = "22",
pages = "1205--1209",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",
number = "6",

}

Lim, S, Lee, S, Han, J, Park, B, Kim, SI, Park, S, Kim, JH, Choi, HJ & Sohn, J 2013, 'Prolonged clinical benefit from the maintenance hormone therapy inpatients with metastatic breast cancer', Breast, vol. 22, no. 6, pp. 1205-1209. https://doi.org/10.1016/j.breast.2013.08.013

Prolonged clinical benefit from the maintenance hormone therapy inpatients with metastatic breast cancer. / Lim, Seungtaek; Lee, Soohyeon; Han, Jungwoo; Park, Byeongwoo; Kim, Seung Il; Park, Seho; Kim, Joo Hang; Choi, Hye Jin; Sohn, Joohyuk.

In: Breast, Vol. 22, No. 6, 01.12.2013, p. 1205-1209.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prolonged clinical benefit from the maintenance hormone therapy inpatients with metastatic breast cancer

AU - Lim, Seungtaek

AU - Lee, Soohyeon

AU - Han, Jungwoo

AU - Park, Byeongwoo

AU - Kim, Seung Il

AU - Park, Seho

AU - Kim, Joo Hang

AU - Choi, Hye Jin

AU - Sohn, Joohyuk

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Objective: We investigated the efficacy of maintenance hormone therapy (MHT), which was given to hormone positive metastatic breast cancer (MBC) patients in non-progression status to the previous chemotherapy. Methods: This study retrospectively analyzed 76 MBC patients who had been treated with MHT from 2006 to 2010 at a single institute. Results: For the 76 patients reviewed, the median progression free survival (PFS) to MHT was 14.4 months (95% CI,11.6-17.3). Prolonged PFS was associated with less previous palliative chemotherapy, fewer metastatic sites, and the absence of visceral metastasis in univariate analysis. Multivariate analysis showed that only the number of previous palliative chemotherapy (HR 1.73, 95% CI, 1.00-2.98; P=0.04) remained as a significant variable. MHT was generally well tolerated. Conclusions: MHT showed considerable efficacy and tolerability in this study. Further randomized prospective study is warranted.

AB - Objective: We investigated the efficacy of maintenance hormone therapy (MHT), which was given to hormone positive metastatic breast cancer (MBC) patients in non-progression status to the previous chemotherapy. Methods: This study retrospectively analyzed 76 MBC patients who had been treated with MHT from 2006 to 2010 at a single institute. Results: For the 76 patients reviewed, the median progression free survival (PFS) to MHT was 14.4 months (95% CI,11.6-17.3). Prolonged PFS was associated with less previous palliative chemotherapy, fewer metastatic sites, and the absence of visceral metastasis in univariate analysis. Multivariate analysis showed that only the number of previous palliative chemotherapy (HR 1.73, 95% CI, 1.00-2.98; P=0.04) remained as a significant variable. MHT was generally well tolerated. Conclusions: MHT showed considerable efficacy and tolerability in this study. Further randomized prospective study is warranted.

UR - http://www.scopus.com/inward/record.url?scp=84887165390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887165390&partnerID=8YFLogxK

U2 - 10.1016/j.breast.2013.08.013

DO - 10.1016/j.breast.2013.08.013

M3 - Article

VL - 22

SP - 1205

EP - 1209

JO - Breast

JF - Breast

SN - 0960-9776

IS - 6

ER -